DelveInsight’s, “Renal Cell Carcinoma Pipeline Insight, 2023,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the Renal Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including Renal Cell Carcinoma clinical trials and nonclinical stage products. It also covers the Renal Cell Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Renal Cell Carcinoma Emerging drugs, the Renal Cell Carcinoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Renal Cell Carcinoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Renal Cell Carcinoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Renal Cell Carcinoma clinical trials studies, Renal Cell Carcinoma NDA approvals (if any), and product development activities comprising the technology, Renal Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Renal Cell Carcinoma Pipeline Report

 

• DelveInsight’s Renal Cell Carcinoma Pipeline analysis depicts a robust space with 30+ active players working to develop 30+ pipeline treatment therapies.

 

• The leading Renal Cell Carcinoma Companies include AstraZeneca, Infinity Pharmaceuticals, Ipsen,  Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc, X4 pharmaceuticals, and others.

 

• Promising Renal Cell Carcinoma Pipeline Therapies include Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab, lenvatinib, everolimus, Sunitinib, Pembrolizumab, IMP321, Ipilimumab, and others.

 

• The Renal Cell Carcinoma companies and academics are working to assess challenges and seek opportunities that could influence R&D. Renal Cell Carcinoma The Renal Cell Carcinoma pipeline therapies under development are focused on novel approaches to treat/improve Renal Cell Carcinoma.

 

Request a sample and discover the recent breakthroughs happening in the Renal Cell Carcinoma Pipeline landscape @ Renal Cell Carcinoma Pipeline Outlook Report

 

Renal Cell Carcinoma Overview

Renal cell carcinoma (RCC) is also called hypernephroma, renal adenocarcinoma, or renal or kidney cancer. Renal cell cancer is a disease in which malignant (cancer) cells form in tubules of the kidney. In early stages Renal carcinoma is symptom free but as the diseases progresses the symptoms may include: lump in the abdomen, fatigue, and unexplained weight loss, blood in the urine, loss of appetite, vision problem, and excessive hair growth. Physical examination, CT scans, complete blood count, urine examination, biopsy may contribute to the diagnosis of renal cell carcinoma.

 

Recent Development Activities in the Renal Cell Carcinoma Treatment Landscape

 

• In November 2021, HUTCHMED Limited and AstraZeneca PLC initiated SAMETA, a global Phase III study of savolitinib (ORPATHYS® in China), an oral, potent, and highly selective small-molecule inhibitor of MET, a receptor tyrosine kinase, in combination with AstraZeneca’s PD-L1 inhibitor IMFINZI® (durvalumab) in patients with MET-driven advanced papillary renal cell carcinoma (“PRCC”).

 

• In August 2021, Exelixis, Inc. announced Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialisation of CABOMETYX® (cabozantinib) in Japan, and Ono Pharmaceutical Co., Ltd. (Ono) received approval from the Japanese Ministry of Health, Labor and Welfare to manufacture and market CABOMETYX in combination with OPDIVO® (nivolumab) as a treatment for unresectable or metastatic renal cell carcinoma (RCC).

 

• In August 2021, Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) for KEYTRUDA, Merck’s anti-PD-1 therapy, for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy (surgical removal of a kidney), or following nephrectomy and resection of metastatic lesions.

 

• In July 2021, Arrowhead Pharmaceuticals Inc. announced positive interim results from the first two cohorts of AROHIF21001, a Phase 1b dose-finding clinical studies of ARO-HIF2, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma (ccRCC). 

 

For further information, refer to the detailed Renal Cell Carcinoma Drugs Launch, Renal Cell Carcinoma Developmental Activities, and Renal Cell Carcinoma News, click here for Renal Cell Carcinoma Ongoing Clinical Trial Analysis

 

Renal Cell Carcinoma Emerging Drugs Profile

 

• CM082: Betta Pharmaceuticals

CM082 series have the similar skeletal structures to Icotinib Hydrochloride, as the multi-target RTK (receptor tyrosine kinase) inhibitor, mainly targeting at VEGFR and PDGFR. The drug is being evaluated in phase III stage of development for the treatment of Renal Cell Carcinoma.

 

• TQB 2450: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

TQB 2450 (formerly APL 502 and CBT 502) is a humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting the programmed cell death-1 ligand-1. Phase III clinical trials are being evaluated by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. for TQB 2450 for the treatment of renal cell carcinoma.

 

• IPI-549: Infinity Pharmaceuticals

IPI-549 is an oral immuno-oncology candidate which has been designed to preferentially inhibit PI3K-gamma. The drug is being studied in phase II stage of development for the treatment of renal cell carcinoma.

 

• CMN-001: ColImmune

Dendritic cells have been used by colimmune for the treatment of renal failure. CMN001 is a dendritic cell vaccine for renal cell carcinoma. The drug is being evaluated in phase II stage of development for the treatment of renal cell carcinoma.

 

Renal Cell Carcinoma Pipeline Therapeutics Assessment

There are approx. 30+ key companies which are developing the therapies for Renal Cell Carcinoma. The companies which have their Renal Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Betta Pharmaceuticals.

 

Renal Cell Carcinoma Pipeline Segmentation

 

Phases

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Route of Administration

• Oral
• Subcutaneous
• Intravenous
• Intramuscular
• Molecule Type

 

Molecule Types

• Bispecific Antibody
• Peptides
• Small molecule
• Gene therapy
• Product Type

 

Find out more about the Renal Cell Carcinoma Pipeline Segmentation, Therapeutics Assessment, and Renal Cell Carcinoma Emerging Drugs @ Renal Cell Carcinoma Treatment Landscape

 

Scope of the Renal Cell Carcinoma Pipeline Report

 

• Coverage- Global

 

• Renal Cell Carcinoma Companies- AstraZeneca, Infinity Pharmaceuticals, Ipsen,  Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc, X4 pharmaceuticals, and others.

 

• Renal Cell Carcinoma Pipeline Therapies- Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab, lenvatinib, everolimus, Sunitinib, Pembrolizumab, IMP321, Ipilimumab, and others.

 

• Renal Cell Carcinoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration 

 

Dive deep into rich insights for drugs for Renal Cell Carcinoma Pipeline Companies and Therapies, click here @ Renal Cell Carcinoma Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Renal Cell Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Renal Cell Carcinoma – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Renal Cell Carcinoma Collaboration Deals
9. Late Stage Products (Phase III)
10. TQB 2450: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. IPI-549: Infinity Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. AVB-S6-500: Aravive Inc.
17. Drug profiles in the detailed report…..
18. Preclinical Stage Products
19. Drug Name: Company name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Renal Cell Carcinoma Key Companies
23. Renal Cell Carcinoma Key Products
24. Renal Cell Carcinoma – Unmet Needs
25. Renal Cell Carcinoma – Market Drivers and Barriers
26. Renal Cell Carcinoma – Future Perspectives and Conclusion
27. Renal Cell Carcinoma Analyst Views
28. Renal Cell Carcinoma Key Companies
29. Appendix

 

Got Queries? Find out the related information on Renal Cell Carcinoma Mergers and acquisitions, Renal Cell Carcinoma Licensing Activities @ Renal Cell Carcinoma Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/